| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.4 | 3.3 | 2.7 |
| Total income | 1.4 | 3.3 | 2.8 |
| Profit before exceptional items & tax | 0.1 | 0.7 | -0.2 |
| Profit before tax | 0.1 | 0.7 | -0.2 |
| Net profit | 0.1 | 0.7 | -0.2 |
| Operating margin | 7.1% | 21.2% | -7.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -85.70% |
|---|---|
| Revenue, year on year | -48.10% |
BSE results filing, NSE: NORRIS. Figures extracted from the filing.
Norris Medicines Ltd: key numbers
- Share price
- ₹15.58
- Market cap
- ₹15.58 Cr
- Revenue (annual)
- ₹8.13 Cr
- Net profit (annual)
- ₹-0.28 Cr
- P/E (TTM)
- -42.5×Sector 47.3×
- Promoter holding
- 34.01%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Norris Medicines Ltd
All →Norris Medicines Annual Report
Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.
Norris Medicines Annual General Meeting
Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.
Norris Medicines Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Widens
Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.4 Cr
Norris Medicines Board Meeting Date
Norris Medicines Limited has scheduled a board meeting for August 14, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.
Norris Medicines Management Change
Norris Medicines Limited has appointed Mr. Iqubal Ismail Patel as the Chief Financial Officer and Key Managerial Personnel, effective July 30, 2026.
Norris Medicines Other Announcement
Norris Medicines Ltd filed its quarterly shareholding pattern as of June 30, 2026. The document lists promoter and public holdings per Regulation 31.